Is PT-141 (Bremelanotide) Legal in Maryland?

The Short Answer on Legality

PT-141 (bremelanotide) is legal in Maryland. Full stop. Because it carries FDA approval under the brand Vyleesi, it sits in standard prescription-drug territory, not in any gray zone. A licensed Maryland clinician, which includes physicians, nurse practitioners, and physician assistants operating within their scope, can legally prescribe it, and a licensed Maryland pharmacy can legally dispense it.

What is not legal is buying it without a prescription, purchasing it labeled as a "research chemical," or sourcing it from an overseas online vendor. Those routes violate federal law regardless of which state you live in.

Why the "Research Chemical" Confusion Exists

Before the 2019 FDA approval, bremelanotide circulated in peptide research markets as PT-141. That pre-approval era created a lasting misconception that it is somehow still a research peptide that anyone can buy freely. It is not. Once a compound receives FDA approval, federal law treats compounded versions and non-prescription sales under stricter rules than it would an unapproved peptide. Think of it this way: approval closed one loophole while opening the mainstream prescription pathway.

Maryland Has No Additional State Restrictions

Maryland does not impose any state-specific restrictions on bremelanotide beyond standard prescription requirements. The Maryland Board of Physicians and the Maryland Board of Nursing regulate prescribers, and the Maryland Board of Pharmacy regulates dispensing pharmacies, but none of these boards have issued bremelanotide-specific prohibitions. Your access is governed almost entirely by federal FDA and DEA frameworks.

Understanding the Federal Framework That Governs Your Access

Because PT-141 is a prescription drug, not a controlled substance, the rules that shape your access come primarily from the FDA rather than the DEA. Understanding these layers helps you avoid both illegal sources and unnecessary confusion about compounding.

FDA Approval Status

The FDA approved bremelanotide (Vyleesi) in June 2019 specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The approval was based on two phase 3 randomized controlled trials, the RECONNECT studies, in which women using bremelanotide reported statistically significant improvements in desire and reductions in distress related to low sexual desire compared with placebo [1].

Approval for a specific indication does not prevent off-label prescribing. A licensed Maryland clinician may prescribe it off-label for other presentations of female sexual dysfunction if they document medical necessity and obtain informed consent.

DEA Schedule Status

Bremelanotide is not a scheduled controlled substance. This distinction matters for you practically: your prescriber does not need a special DEA waiver to prescribe it, it does not appear on your state's Prescription Drug Monitoring Program (PDMP) in the same way opioids or benzodiazepines do, and there is no federally mandated limit on how many refills a prescription can carry. Maryland does require PDMP checks for controlled substances; that requirement does not apply here.

The 503A and 503B Compounding Question

This is where women often receive incomplete answers. Compounded bremelanotide is not on the FDA's Current Bulk Drug Substances List for 503A pharmacies as of the 2025 update. That matters because:

• A 503A pharmacy (a traditional compounding pharmacy serving individual patients) may still compound bremelanotide if a prescriber writes for a specific patient with a documented clinical need and the pharmacy sources an FDA-registered bulk API supplier. The drug being absent from the positive Bulks List does not make compounding automatically illegal, but it places a higher burden of documentation on the prescriber and the pharmacy.
• A 503B outsourcing facility (which produces large batches for healthcare settings) faces more restrictions. Compounding a drug that is essentially a copy of an FDA-approved product without a specific patient-by-patient justification risks violating the Federal Food, Drug, and Cosmetic Act Section 503B.

The practical implication for you in Maryland: if a telehealth platform offers compounded bremelanotide at a lower cost than brand-name Vyleesi, ask specifically which type of pharmacy compound it, whether the pharmacy is 503A-registered with the Maryland Board of Pharmacy, and how they document medical necessity. A reputable platform will answer all three questions without hesitation.

How PT-141 Works: The Biology Matters for Women

Bremelanotide works through a mechanism that is fundamentally different from every other treatment approved for female sexual dysfunction. This is not incidental. Understanding the mechanism helps you set realistic expectations and helps your clinician assess whether it suits your specific hormonal context.

Melanocortin Receptor Activation, Not Hormonal Manipulation

PT-141 is a cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (alpha-MSH). It activates melanocortin receptors, primarily MC3R and MC4R, in the central nervous system, particularly in the hypothalamus [2]. The result is increased dopaminergic signaling in pathways associated with sexual motivation and desire.

This mechanism is central, not peripheral. Unlike phosphodiesterase-5 inhibitors (which increase genital blood flow) or testosterone (which acts on androgen receptors in multiple tissues), bremelanotide acts on the brain circuits that generate desire itself. For women, whose sexual response is often more heavily influenced by central motivational circuitry than by peripheral vascular changes, this distinction is clinically relevant.

How Your Hormonal Status Affects Response

The RECONNECT trials enrolled 1,179 premenopausal women across 24 weeks of treatment. Perimenopausal and postmenopausal women were explicitly excluded from the key trials, which is a genuine evidence gap. What this means:

• Reproductive years (cycling women): The primary evidence base. Bremelanotide showed meaningful reductions in distress and improvements in desire regardless of cycle phase in the RECONNECT trials.
• Perimenopause: No controlled trial data exist specifically in perimenopausal women. Prescribing in this life stage is off-label and extrapolated from the premenopausal data. Some clinicians use it alongside systemic hormone therapy when HSDD coexists with vasomotor symptoms, but that combination has not been studied in a randomized trial.
• Post-menopause: Also off-label. The Menopause Society (formerly NAMS) notes that HSDD in postmenopausal women is common but that bremelanotide's evidence base in this group is limited.

The data gap in women over 50 is real. If your clinician proposes bremelanotide during perimenopause or after menopause, ask specifically what evidence supports it in your life stage and whether other options, including systemic testosterone or flibanserin, have been considered.

Female-Specific Conditions Where PT-141 May Be Considered

HSDD does not occur in a hormonal vacuum. Several gynecological and endocrine conditions that disproportionately affect women can either cause or worsen hypoactive sexual desire, and the decision to use bremelanotide should account for them.

PCOS and Androgen Excess

Women with polycystic ovary syndrome (PCOS) have complex hormonal profiles. Some have elevated androgens that might support libido; others have insulin resistance or depression that suppresses it. There are no PCOS-specific trials of bremelanotide. If low desire in a woman with PCOS coexists with depression or an SSRI prescription, that context should be addressed before or alongside bremelanotide, because SSRIs independently reduce desire through a different mechanism than HSDD.

Postpartum and Lactating Women

This deserves its own section (covered fully below), but the short version is: bremelanotide is not approved for use during breastfeeding, and data are absent.

Hypothyroidism and Thyroid Dysfunction

Thyroid disorders are significantly more common in women than men. Hypothyroidism independently reduces libido. Before attributing low desire to HSDD, your Maryland prescriber should confirm that your thyroid function is optimized. Treating undertreated hypothyroidism may resolve low desire without any additional medication.

GSM (Genitourinary Syndrome of Menopause)

Low desire in menopausal women is sometimes driven by pain during sex rather than a central desire deficit. Bremelanotide addresses central motivation; it does not treat vaginal dryness or dyspareunia. If GSM is the primary driver, local vaginal estrogen or ospemifene may be more appropriate first-line options, per ACOG Clinical Practice Bulletin No. 141.

Pregnancy, Lactation, and Contraception

Bremelanotide is contraindicated in pregnancy. This is not a precautionary soft warning. It is a hard contraindication.

Pregnancy Safety Data

Animal reproduction studies showed fetal harm at doses below the human therapeutic dose [3]. Human pregnancy data are absent because pregnant women were excluded from all trials. The FDA label states explicitly: discontinue bremelanotide if you become pregnant or are planning to become pregnant. Because HSDD by definition involves sexual activity, and because bremelanotide is used just before sexual activity, an unintended pregnancy is a realistic risk in the absence of reliable contraception.

If you are trying to conceive, do not use bremelanotide. Discuss low desire with your reproductive endocrinologist or OB-GYN in that context. Psychosexual therapy and addressing underlying hormonal contributors are the appropriate tools during the trying-to-conceive phase.

What to Do If You Become Pregnant While Using It

Stop bremelanotide immediately and contact your OB-GYN. There is a bremelanotide pregnancy exposure registry managed through AMAG Pharmaceuticals (now Palatin Technologies' licensee). Enrollment is voluntary but provides data that may eventually help other women. Your clinician can provide the registry contact information.

Lactation

No human data exist on bremelanotide transfer into breast milk. Animal studies show transfer into milk. Because the safety profile for an infant is completely unknown, the FDA label advises against use during breastfeeding. If you are postpartum and experiencing low desire, which is extremely common and often driven by prolactin elevation and sleep deprivation rather than HSDD per se, discuss the timeline of return of desire with your provider before considering any pharmacological intervention. For many postpartum women, desire returns as breastfeeding frequency decreases and sleep improves, without any medication.

Contraception Requirements

Any woman of reproductive potential using bremelanotide should use reliable contraception. Bremelanotide has no known interaction with combined hormonal contraceptives, progestin-only methods, or IUDs based on current data, but the teratogenic risk from animal studies means the margin for error is not acceptable.

Who This Treatment Is Right For, and Who It Is Not

You May Be a Candidate If:

• You are a premenopausal woman with acquired HSDD (desire was present before and has declined) rather than lifelong low desire
• Your HSDD is generalized (not situational to a specific partner or context)
• You have completed a thyroid panel, screened for depression, and reviewed your current medications for libido-suppressing effects (SSRIs, antiandrogens, combined oral contraceptives)
• You are not pregnant, not trying to conceive, and not breastfeeding
• Your Maryland prescriber has documented a diagnosis of HSDD using a validated tool such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS)

You Are Not a Candidate If:

• You are pregnant, trying to conceive, or currently breastfeeding
• Your low desire is primarily driven by relationship conflict, sexual trauma, or depression (psychotherapy is first-line in these cases)
• You have uncontrolled hypertension. Bremelanotide transiently raises blood pressure by approximately 2 to 4 mmHg systolic and 1 to 3 mmHg diastolic for about 12 hours after each dose. Women with cardiovascular disease or hypertension that is not well controlled should not use it.
• You are taking naltrexone, which significantly reduces bremelanotide's efficacy through competitive receptor binding

How to Access Bremelanotide Legally in Maryland

Getting a legal prescription in Maryland follows the same path as any other prescription-only medication. The steps below apply whether you pursue in-person or telehealth care.

Step 1: Find a Qualified Maryland Prescriber

Your primary care physician, OB-GYN, urogynecologist, or a women's health nurse practitioner licensed in Maryland can prescribe bremelanotide. Telehealth platforms licensed to operate in Maryland can also prescribe it via synchronous video visit, which qualifies under Maryland's telemedicine prescribing rules for non-controlled substances. Maryland adopted permanent telehealth prescribing rules after the COVID-era flexibilities, allowing ongoing care without a mandatory in-person first visit for most drug classes.

Step 2: Prepare for the Consultation

Bring or be ready to discuss:

• Duration and onset of low desire (acquired vs. Lifelong)
• Current medications (especially antidepressants, hormonal contraceptives, antiandrogens)
• Recent thyroid function tests (TSH, free T4)
• Blood pressure history
• Contraceptive status and pregnancy plans
• Any history of cardiovascular disease or fainting episodes

Step 3: Pharmacy Dispensing Options in Maryland

Once prescribed, you have two options.

Brand-name Vyleesi is dispensed through specialty pharmacies. As of 2025, it is not stocked at most retail chains. Your prescriber or telehealth platform will coordinate with a specialty pharmacy. Cash pricing runs high (over $900 per auto-injector without insurance), and insurance coverage is inconsistent. Many Maryland commercial plans cover it with prior authorization for women with a documented HSDD diagnosis; Medicaid coverage in Maryland is limited.

Compounded bremelanotide from a 503A pharmacy is the more affordable route for many women, typically ranging from $50 to $200 per vial depending on concentration and volume. Confirm the pharmacy holds a Maryland Board of Pharmacy license and sources pharmaceutical-grade API. Ask for a certificate of analysis (CoA) for every compounded batch.

Step 4: What Legitimate Telehealth Looks Like

A legal Maryland telehealth prescription for bremelanotide requires a real synchronous clinical encounter (not just a questionnaire), a documented diagnosis, informed consent that addresses the pregnancy contraindication and blood pressure risk, and a prescription sent to a licensed pharmacy. Any platform that ships bremelanotide without a live clinical encounter is operating outside the rules.

Side Effects Women Report Most Often

The RECONNECT trials reported that 40% of women experienced nausea, making it the most common side effect. Most cases were mild to moderate and occurred within one hour of injection, resolving within two hours. Flushing occurred in approximately 20% and was transient. Injection-site bruising and hyperpigmentation, particularly on the face, gums, and breasts, occurred with repeated use in a smaller subset.

The transient blood pressure increase is the most clinically significant safety signal. Take your blood pressure 45 minutes after the first dose if you have any cardiovascular risk factors. Do not use within two hours of driving or operating machinery if nausea is pronounced.

Limit use to one injection per 24 hours and no more than one injection per anticipated sexual activity event. There is no approved daily dosing regimen.

The Evidence Gap: What We Still Do Not Know in Women

Women were historically under-represented in clinical drug trials. Bremelanotide is one of the rare drugs studied exclusively in women for its approved indication, which is a genuine strength of its evidence base for premenopausal HSDD. The gaps, however, are real:

• No long-term safety data beyond 52 weeks of intermittent use exist in published literature.
• Perimenopausal and postmenopausal women were excluded from all key trials.
• Data on use with hormonal IUDs, combined oral contraceptives, or systemic hormone therapy are observational at best.
• The clinical meaning of the FSFI changes seen in RECONNECT (a mean improvement of approximately 0.6 points on the desire subscale vs. Placebo) is debated. The Menopause Society notes that statistically significant improvements do not always translate to clinically meaningful benefit for every individual woman.

As Dr. Sheryl Kingsberg, a leading researcher in female sexual dysfunction and an author on the RECONNECT trial publications, has stated: "HSDD is the most common female sexual dysfunction, yet it remains underdiagnosed and undertreated in clinical practice." The existence of FDA-approved options does not remove the need for individualized assessment.